Revenue from operations₹180.21 Cr
SENORES · What Changed
What Changed at
Senores Pharmaceuticals Limited?
See reported financial changes and material NSE disclosures for Senores Pharmaceuticals Limited.
My CompaniesSaved on this device. No account needed.
Follow a company to build your personal change feed.
Latest company changes
Senores Pharmaceuticals Limited
Start with what changed, then open the supporting financial and operating detail only when you need it.
SENORES · Consolidated
Senores Pharmaceuticals Limited
Latest reported period
Latest reported changes
What Actually Changed
Worth reviewingNeutral / mixedNSE disclosure · 13 Oct 2026GovernanceThe company disclosed the company filed a governance update concerning directors, KMP, senior management, auditors or its RTA.
+
Worth reviewingNeutral / mixedNSE disclosure · 13 Oct 2026ManagementPharmaceuticals Limited has informed the Exchange that the Board of Directors of the Company at their Meeting held today i.e.
+
Worth reviewingNeutral / mixedNSE disclosure · 13 Oct 2026ManagementChetan Bipinchandra Shah was appointed as Whole Time Director.
+
Financial snapshot
Latest Reported Financials
Available reported figures from the latest period.
Total income₹183.02 Cr
Profit after tax₹30.45 Cr
EPS₹6.61
Profit before tax₹39.46 Cr
Supporting financial context
Margins and Supporting Figures
Only reported or directly calculated figures that are available for this company.
PAT margin16.90%
Profit before tax₹39.46 Cr
Finance cost₹7.17 Cr
Depreciation₹9.94 Cr
Tax₹9.01 Cr
Other income₹2.81 Cr
Today
Loading today’s changes…Today on Nivata
— meaningful changes— companies
Checking the latest tracked company developments…